Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies

Abstract Background The aim of this pooled analysis was to evaluate the efficacy and safety of lurasidone in the treatment of an acute exacerbation of schizophrenia in adolescents and young adults. Methods The six pooled studies in this analysis used similar study designs and outcome measures. P...

Full description

Bibliographic Details
Published in:	European Psychiatry
Main Authors:	Isabella Costamagna, Fabrizio Calisti, Agnese Cattaneo, Jay Hsu, Michael Tocco, Andrei Pikalov, Robert Goldman
Format:	Article
Language:	English
Published:	Cambridge University Press 2021-01-01
Subjects:	adolescent atypical antipsychotic lurasidone schizophrenia treatment-naïve
Online Access:	https://www.cambridge.org/core/product/identifier/S0924933821000304/type/journal_article

Similar Items

Long-term safety and effectiveness of lurasidone in adolescents and young adults with schizophrenia: pooled post hoc analyses of two 12-month extension studies
by: Fabrizio Calisti, et al.
Published: (2024-07-01)

Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia
by: Christoph U. Correll, et al.
Published: (2022-01-01)

Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: Pooled analysis of double-blind, placebo-controlled 6-week studies
by: F. Calisti, et al.
Published: (2021-04-01)

Lurasidone in adolescents with schizophrenia: Sustained remission and recovery during 2 years of open-label treatment
by: M. Tocco, et al.
Published: (2021-04-01)

Effect of Lurasidone on Life Engagement in Schizophrenia: Post-Hoc Analysis of the JEWEL Study
by: Maruyama H, et al.
Published: (2024-07-01)

Real-world treatment patterns and outcomes in patients initiating lurasidone for the treatment of schizophrenia in Europe
by: A. Jones, et al.
Published: (2022-06-01)

Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy
by: Miura I, et al.
Published: (2023-09-01)

Changes in the pharmacokinetics of lurasidone in a pregnant woman with schizophrenia
by: Mihoko Kawai, et al.
Published: (2024-12-01)

The Role of Lurasidone in Managing Depressive Symptoms in People with Schizophrenia: A Review
by: Andrea Fiorillo, et al.
Published: (2024-02-01)

Hospitalization Risk for Adults with Bipolar I Disorder Treated with Oral Atypical Antipsychotics as Adjunctive Therapy with Mood Stabilizers: A Retrospective Analysis of Medicaid Claims Data
by: Xiaoli Niu, PhD, et al.
Published: (2021-01-01)

Clinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression
by: Alexander M. Reznik, et al.
Published: (2022-09-01)

Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel
by: Miquel Bernardo, et al.
Published: (2025-01-01)

Lurasidone for Pediatric Bipolar Disorder: A Systematic Review
by: Alexia Koukopoulos, et al.
Published: (2025-06-01)

Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia
by: Brian J. Miller, et al.
Published: (2020-10-01)

Lurasidone-induced mania: A case report
by: T. Fernández, et al.
Published: (2022-06-01)

Efficacy and tolerability of lurasidone in schizophrenia: A systematic review and meta-analysis of short-term, randomized, placebo controlled trials
by: K. Hagi, et al.
Published: (2021-04-01)

Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom
by: Amy Dymond, et al.
Published: (2022-08-01)

Lurasidone treatment for delusional infestation in a patient with dementia
by: Yu-Ning Her, et al.
Published: (2023-01-01)

Lurasidone in treatment of manic episode
by: I. Sánchez-Rivero
Published: (2022-06-01)

Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
by: Jia Liu, et al.
Published: (2022-09-01)

Lurasidone for the treatment of schizophrenia in adult and paediatric populations
by: Teresa Guilera, et al.
Published: (2023-02-01)

Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
by: Jia Liu, et al.
Published: (2022-11-01)

So, was Kraepelin right? An attempt to clarify the relationship between schizophrenia and bipolar disorder
by: Azat R. Asadullin, et al.
Published: (2023-06-01)

Treatment satisfaction and effectiveness of Lurasidone on quality of life and functioning in adult patients with schizophrenia in the real-world Italian clinical practice: a prospective 3-month observational study
by: Sergio De Filippis, et al.
Published: (2024-11-01)

Valuable interaction with cognitive remediation and optimal antipsychotics for recovery in schizophrenia (VICTORY-S): study protocol for an interventional, open-label, randomized comparison of combined treatment with cognitive remediation and lurasidone or paliperidone
by: Ryotaro Kubota, et al.
Published: (2024-02-01)

Bioequivalence study of two formulations of lurasidone film coated tablets in healthy subjects under fed conditions
by: Gökçe Sözer, et al.
Published: (2025-07-01)

Lurasidone treatment in a delusional disorder patient with atrial fibrillation: A case report
by: S. Marini, et al.
Published: (2021-04-01)

Towards full recovery with lurasidone: effective doses in the treatment of agitation, affective, positive and cognitive symptoms in schizophrenia, and dual psychosis
by: María Teresa Guarro Carreras, et al.
Published: (2024-08-01)

Going for a stroll on lurasidone: Considerations on an atypical case of acute compartment syndrome of both legs
by: L. Bosco, et al.
Published: (2023-04-01)

Augmentation strategy fluoxetine and lurasidone in the treatment of OCD with comorbid Restrictive Anorexia: a case report
by: L. Orsolini, et al.
Published: (2022-06-01)

Lurasidone versus Quetiapine for Cognitive Impairments in Young Patients with Bipolar Depression: A Randomized, Controlled Study
by: Xiangyuan Diao, et al.
Published: (2022-11-01)

Rash caused by lurasidone in old chinese patient with bipolar disorder: case-based review
by: Wenjuan Yang, et al.
Published: (2024-07-01)

Epilepsy and psychosis: navigating through a complex intersection
by: Marco Mula, et al.
Published: (2025-07-01)

Lurasidone induces developmental toxicity and behavioral impairments in zebrafish embryos
by: Wentian Li, et al.
Published: (2025-07-01)

Identification of lurasidone as a potent inhibitor of severe fever with thrombocytopenia syndrome virus by targeting the viral nucleoprotein
by: Ting Cheng, et al.
Published: (2025-04-01)

A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression
by: Taro Kishi, et al.
Published: (2023-03-01)

Escitalopram, bupropion, lurasidone, lamotrigine and possible vortioxetine overdose presented with serotonin syndrome and diffuse encephalopathy: A case report
by: Suthimon Thumtecho, et al.
Published: (2021-01-01)

Third-Generation Antipsychotics: The Quest for the Key to Neurotrophism
by: Federico Mucci, et al.
Published: (2025-03-01)

Lurasidone uses and dosages in Spain: RETROLUR, a real-world retrospective analysis using artificial intelligence
by: Fernando Mora, et al.
Published: (2025-02-01)

NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial
by: Andrew Nierenberg, et al.
Published: (2023-08-01)